Literature DB >> 27639256

Skin biopsy utilization and melanoma incidence among Medicare beneficiaries.

M A Weinstock1,2,3, J P Lott4, Q Wang5, L J Titus6,7, T Onega6,7,8, H D Nelson9,10, L Pearson5, M Piepkorn11,12, R L Barnhill13, J G Elmore14, A N A Tosteson5,6,15.   

Abstract

BACKGROUND: Melanoma incidence has increased in recent decades in the U.S.A. Uncertainty remains regarding how much of this increase is attributable to greater melanoma screening activities, potential detection bias and overdiagnosis.
OBJECTIVES: To use a cross-sectional ecological analysis to evaluate the relationship between skin biopsy and melanoma incidence rates over a more recent time period than prior reports.
METHODS: Examination of the association of biopsy rates and melanoma incidence (invasive and in situ) in SEER-Medicare data (including 10 states) for 2002-2009.
RESULTS: The skin biopsy rate increased by approximately 50% (6% per year) throughout this 8-year period, from 7012 biopsies per 100 000 persons in 2002 to 10 528 biopsies per 100 000 persons in 2009. The overall melanoma incidence rate increased approximately 4% (< 1% per year) over the same time period. The incidence of melanoma in situ increased approximately 10% (1% per year), while the incidence of invasive melanoma increased from 2002 to 2005 then decreased from 2006 to 2009. Regression models estimated that, on average, for every 1000 skin biopsies performed, an additional 5·2 (95% confidence interval 4·1-6·3) cases of melanoma in situ were diagnosed and 8·1 (95% confidence interval 6·7-9·5) cases of invasive melanoma were diagnosed. When considering individual states, some demonstrated a positive association between biopsy rate and invasive melanoma incidence, others an inverse association, and still others a more complex pattern.
CONCLUSIONS: Increased skin biopsies over time are associated with increased diagnosis of in situ melanoma, but the association with invasive melanoma is more complex.
© 2016 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2017        PMID: 27639256      PMCID: PMC5357200          DOI: 10.1111/bjd.15077

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  11 in total

Review 1.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

2.  South Korea's Thyroid-Cancer "Epidemic"--Turning the Tide.

Authors:  Hyeong Sik Ahn; H Gilbert Welch
Journal:  N Engl J Med       Date:  2015-12-10       Impact factor: 91.245

3.  The cost implications of prostate cancer screening in the Medicare population.

Authors:  Xiaomei Ma; Rong Wang; Jessica B Long; Joseph S Ross; Pamela R Soulos; James B Yu; Danil V Makarov; Heather T Gold; Cary P Gross
Journal:  Cancer       Date:  2013-10-04       Impact factor: 6.860

4.  Early diagnosis of cutaneous malignant melanoma at Lawrence Livermore National Laboratory.

Authors:  J S Schneider; D H Moore; R W Sagebiel
Journal:  Arch Dermatol       Date:  1990-06

5.  Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany.

Authors:  Andreas Stang; Karl-Heinz Jöckel
Journal:  Cancer       Date:  2015-10-19       Impact factor: 6.860

6.  Skin biopsy rates and incidence of melanoma: population based ecological study.

Authors:  H Gilbert Welch; Steven Woloshin; Lisa M Schwartz
Journal:  BMJ       Date:  2005-08-04

7.  Skin Cancer Screening in Germany. Documenting Melanoma Incidence and Mortality From 2008 to 2013.

Authors:  Alexander Katalinic; Nora Eisemann; Annika Waldmann
Journal:  Dtsch Arztebl Int       Date:  2015-09-18       Impact factor: 5.594

8.  Does skin cancer screening save lives?: an observational study comparing trends in melanoma mortality in regions with and without screening.

Authors:  Alexander Katalinic; Annika Waldmann; Martin A Weinstock; Alan C Geller; Nora Eisemann; Ruediger Greinert; Beate Volkmer; Eckhard Breitbart
Journal:  Cancer       Date:  2012-04-19       Impact factor: 6.860

9.  Increasing burden of melanoma in the United States.

Authors:  Eleni Linos; Susan M Swetter; Myles G Cockburn; Graham A Colditz; Christina A Clarke
Journal:  J Invest Dermatol       Date:  2009-01-08       Impact factor: 8.551

10.  Melanoma thickness trends in the United States, 1988-2006.

Authors:  Vincent D Criscione; Martin A Weinstock
Journal:  J Invest Dermatol       Date:  2009-10-15       Impact factor: 8.551

View more
  8 in total

1.  Rates of Dermoscopy Use for Melanoma Diagnosis in the Miami VA Medical Center.

Authors:  Lucy L Chen; Erin X Wei; Fangchao Ma; Jonette Keri; Shasa Hu
Journal:  JAMA Dermatol       Date:  2017-06-01       Impact factor: 10.282

2.  Population-Based Analysis of Histologically Confirmed Melanocytic Proliferations Using Natural Language Processing.

Authors:  Jason P Lott; Denise M Boudreau; Ray L Barnhill; Martin A Weinstock; Eleanor Knopp; Michael W Piepkorn; David E Elder; Steven R Knezevich; Andrew Baer; Anna N A Tosteson; Joann G Elmore
Journal:  JAMA Dermatol       Date:  2018-01-01       Impact factor: 10.282

3.  An Epidemiologic Analysis of Melanoma Overdiagnosis in the United States, 1975-2017.

Authors:  Nicholas R Kurtansky; Stephen W Dusza; Allan C Halpern; Rebecca I Hartman; Alan C Geller; Ashfaq A Marghoob; Veronica M Rotemberg; Michael A Marchetti
Journal:  J Invest Dermatol       Date:  2021-12-11       Impact factor: 7.590

Review 4.  Incidence of diseases primarily affecting the skin by age group: population-based epidemiologic study in Olmsted County, Minnesota, and comparison with age-specific incidence rates worldwide.

Authors:  Laurel L Wessman; Louise K Andersen; Mark D P Davis
Journal:  Int J Dermatol       Date:  2018-01-29       Impact factor: 2.736

5.  Melanoma screening: Informing public health policy with quantitative modelling.

Authors:  Stephen Gilmore
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

6.  Automated decision support in melanocytic lesion management.

Authors:  Stephen J Gilmore
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

7.  Assessment of Second-Opinion Strategies for Diagnoses of Cutaneous Melanocytic Lesions.

Authors:  Michael W Piepkorn; Gary M Longton; Lisa M Reisch; David E Elder; Margaret S Pepe; Kathleen F Kerr; Anna N A Tosteson; Heidi D Nelson; Stevan Knezevich; Andrea Radick; Hannah Shucard; Tracy Onega; Patricia A Carney; Joann G Elmore; Raymond L Barnhill
Journal:  JAMA Netw Open       Date:  2019-10-02

8.  Phellinus gilvus‑derived protocatechualdehyde induces G0/G1 phase arrest and apoptosis in murine B16‑F10 cells.

Authors:  Shi Zhong; Qinshen Jin; Taihen Yu; Jianxun Zhu; Yougui Li
Journal:  Mol Med Rep       Date:  2019-12-19       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.